Forest Road Acquisition Corp. (FRX) NYSE
12.00
+0.78(+6.95%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
12.00
+0.78(+6.95%)
Currency In USD
| Previous Close | 11.22 |
| Open | 11.36 |
| Day High | 12.33 |
| Day Low | 11.4 |
| 52-Week High | 18.2 |
| 52-Week Low | 9.24 |
| Volume | 3.96M |
| Average Volume | 1.57M |
| Market Cap | 3.75B |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 10.29 |
| Moving Average 200 Days | 10.64 |
| Change | 0.78 |
Data not available
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
GlobeNewswire Inc.
Mar 04, 2026 12:05 PM GMT
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid Tumors Receiving Cisplatin Chemothe
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
GlobeNewswire Inc.
Feb 20, 2026 12:03 PM GMT
– Administration of PEDMARK® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation Highlight the Potential of PEDMARK® to Address
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
GlobeNewswire Inc.
Dec 26, 2025 10:44 PM GMT
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it